Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
Holding IPHYF?
Track your performance easily
IPHYF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $3.22
Previous Close$1.28
Volume100.00
Average Volume (3M)1.05K
Market Cap
$122.91M
Enterprise Value$75.09M
Total Cash (Recent Filing)€92.46M
Total Debt (Recent Filing)€47.54M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Sep 12, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding318,170,508
10 Day Avg. Volume10
30 Day Avg. Volume1,050
Standard Deviation0.20
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.27Price Target Upside155.47% Upside
Rating ConsensusHold
Number of Analyst Covering2
Innate Pharma SA News
PremiumCompany Announcements
Innate Pharma’s New CEO and Promising FDA Feedback
PremiumCompany Announcements
Innate Pharma Showcases Promising Cancer Therapies
PremiumCompany Announcements
Innate Pharma SA to Unveil Q3 2024 Updates
PremiumCompany Announcements
Innate Pharma to Engage Investors at Global Conferences
PremiumCompany Announcements
Innate Pharma Appoints New CEO to Drive Growth
PremiumCompany Announcements
Innate Pharma Hosts Immunotherapy Symposium
PremiumCompany Announcements
Innate Pharma Advances Novel Cancer TreatmentOwnership Overview
―
Insiders
0.03% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IPHYF FAQ
What was Innate Pharma SA’s price range in the past 12 months?
Innate Pharma SA lowest stock price was $1.25 and its highest was $3.22 in the past 12 months.
What is Innate Pharma SA’s market cap?
Currently, no data Available
When is Innate Pharma SA’s upcoming earnings report date?
Innate Pharma SA’s upcoming earnings report date is Sep 12, 2024 which is 65 days ago.
How were Innate Pharma SA’s earnings last quarter?
Innate Pharma SA released its earnings results on Mar 21, 2024. The company reported -$0.128 earnings per share for the quarter, beating the consensus estimate of -$0.429 by $0.301.
Is Innate Pharma SA overvalued?
According to Wall Street analysts Innate Pharma SA’s price is currently Undervalued.
Does Innate Pharma SA pay dividends?
Innate Pharma SA does not currently pay dividends.
What is Innate Pharma SA’s EPS estimate?
Innate Pharma SA’s EPS estimate is -$0.3.
How many shares outstanding does Innate Pharma SA have?
Innate Pharma SA has 80,967,410 shares outstanding.
What happened to Innate Pharma SA’s price movement after its last earnings report?
Innate Pharma SA reported an EPS of -$0.128 in its last earnings report, beating expectations of -$0.429. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Innate Pharma SA?
Currently, no hedge funds are holding shares in IPHYF
---
Innate Pharma SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.49%
12-Months-Change
Fundamentals
Return on Equity
-78.33%
Trailing 12-Months
Asset Growth
-25.23%
Trailing 12-Months
Company Description
Innate Pharma SA
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
---
IPHYF Company Deck
---
IPHYF Earnings Call
Q2 2024
0:00 / 0:00
---
IPHYF Stock 12 Month Forecast
Average Price Target
$3.27
▲(155.47% Upside)
Technical Analysis
---